Clinical Trials

Date: 2017-04-04

Type of information: Presentation of results at a congress

phase: preclinical

Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting

Company: Evotec (Germany) Exscientia (UK)

Product: bispecific small molecules

Action mechanism: adenosine A2A receptor antagonist. The adenosine pathway is one of the main drivers of tumour progression by acting on two key features of the tumour micro-environment; evasion of the host immune system and angiogenesis. Expression of CD73 on tumour cells and on immunosuppressive cell subsets leads to the generation of adenosine. Adenosine inhibits the biological functions of T lymphocytes infiltrating the tumour by binding to A2AR.

Disease:

Therapeutic area: Cancer - Oncology

Country:

Trial details:

Latest news:

• • On April 4, 2017, Exscientia announced that the latest results of its collaboration with Evotec to develop adenosinergic small molecules focused on immuno-oncology will be presented at the American Association for Cancer Research (AACR) Annual Meeting (Washington, DC, USA).
• Highlights of the poster include presentation of a selective adenosine 2A receptor (A2AR) antagonist, currently being explored for candidate selection, as well as first demonstration of a bispecific small molecule (a single, low molecular weight compound with dual pharmacology) capable of simultaneously antagonising A2AR and inhibiting CD73.
• The presentation details are as follows: Targeting the adenosine immunosuppressive pathway for cancer immunotherapy with small molecule agents. A2AR, CD73 specific and A2AR/CD73 Bispecific small molecules for Immuno-Oncology.

 

Is general: Yes